Rising Prescriptions and Complications1
- In a study involving 2251 patients, 52.3% of them experienced GERD symptoms after NSAID treatment.
- Over half of these patients lack adequate gastroprotection during NSAID treatment.
Need for Gastroprotection2
- Discontinuing NSAIDs is often not feasible due to recurring pain and impact on quality of life.
- Preventing mucosal injury while continuing NSAID therapy is crucial.
Treatment: Gastric Acid Secretory Inhibitors2
- PPIs: Improved gastric acid-related conditions since the late 1980s
- P-CABs: Emerged to promote better antisecretory effects and address unmet needs in acid-related disease management
Vonoprazan: A New Alternative2
 |
Recommended for preventing NSAID-related peptic ulcer recurrence in at-risk patients |  |
Potentially a useful alternative to PPIs, especially for high-risk individuals |
Vono-Always on Duty
Vono, containing Vonoprazan molecule, is a Potassium Competitive Acid Blocker which helps in treatment of Refractory GERD, Erosive Esophagitis, H.Pylori, Gastric & Duodenal Ulcers
